Amarin Corp Plc (AMRN)

[Thonn]

Thank you for your comments.

I agree with what you say, although I would like to make a nuance: they would not be reducing the number of gV scripts, they would be increasing the number of branded Vascepa scripts (in other words, increasing the number of vascepa + gV globally). The number of gV scripts would not be reduced because of what I have mentioned before: it would be prescribed by other insurers.

Therefore, we would only be adding the scripts that previously tried to change to gV without success. Unfortunately we do not have access to data on scripts that are not being filled. It could be a lot, in which case we should see a weekly increase, or a few, in which case we probably won't notice a difference.

To estimate this number, perhaps the term New-to-Brand (NBRx) that Karim presented to us at the last conference is a good indicator, since part of these "new people" may be the ones who are not being able to fill out their script...(?)
I don't know.

Thonn